ESTRO 2024 - Abstract Book

S2306

Clinical - Urology

ESTRO 2024

advanced imaging test were performed, (table 1). The median follow-up for the entire group was 91 months (16 229), and for patients who experienced subsequent BCR, the time to this recurrence was 50 months (3-188). Out of the 307 patients who experienced metastasis progression, the median time to metastasis progression from initial recurrence was 58 months (4-163). Median metastasis progression free-survival from initial biochemical recurrence, was 67 months (0-74) in the general population, 39 months (26-66) in the EMBARK population, and 74 months (66 NR) in the non-EMBARK population, p=0.0027, (figure 1). Median global survival from biochemical recurrence was 94 months (91-NR). However, in the EMBARK population, the median global survival has not been reached. In the non EMBARK population, the median global survival from biochemical recurrence was 94 months (85-NR), p=0.24.